The firm backed the insurance broker's creation in 2011, sold a majority stake in 2015 and reacquired it in 2019. Mao Geping Cosmetics shares jumped in their trading debut in Hong Kong after an ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
They are currently approved for treating diabetes, obesity and those with a history of cardiovascular disease in people who ...
According to a sneak peek of the data from one of Eli Lilly's (NYSE: LLY) late-stage clinical trials, the cardiometabolic medicine juggernaut now looks even stronger in comparison to its similarly ...
As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according ...
Novo Nordisk is a bargain stock with tremendous growth potential. Vertex Pharmaceuticals has seven clear paths to growth ...
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
To receive the full newsletter in your inbox for free sign up here) An experimental immunotherapy drug is a potentially effective treatment for patients with bladder cancer who no longer respond to ...
The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of ...
Novo Holdings, which owns a controlling stake in Wegovy-maker Novo Nordisk, agreed to buy Catalent in February for $16.5 billion, including debt. In turn, Novo Holdings will flip three of the most ...
As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...